Forte Biosciences
FBRX
31 hedge funds and large institutions have $3.9M invested in Forte Biosciences in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 3 closing their positions.
3,300% more call options, than puts
Call options by funds: $34K | Put options by funds: $1K
3% more capital invested
Capital invested by funds: $3.8M → $3.9M (+$102K)
0.01% more ownership
Funds ownership: 0.72% → 0.74% (+0.01%)
9% less funds holding
Funds holding: 34 → 31 (-3)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$275K |
| 2 |
Millennium Management
New York
|
+$31.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.85K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$755 |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$528 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$139K |
| 2 |
Renaissance Technologies
New York
|
-$64.4K |
| 3 |
BlackRock
New York
|
-$20.6K |
| 4 |
FIA
FNY Investment Advisers
New York
|
-$7K |
| 5 |
Two Sigma Advisers
New York
|
-$5.63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $133 | – | – | – |
|
27
Citadel Advisors
Miami,
Florida
| $68 | -$4.53K | -180 | -98% |
|
|
LFG
28
Larson Financial Group
St Louis,
Missouri
| $35 | – | – | – |
|
|
FIA
29
FNY Investment Advisers
New York
| – | -$7K | -300 | Closed |
|
30
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1.79K | -72 | Closed |
|
|
TWC
31
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$104 | -4 | Closed |
|
FBRX Hedge Fund Activity: Q1 2023 in Review
31 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q1 2023, worth a combined $3.9M — up 2.7% from $3.8M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FBRX and 0 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was BML Capital Management, adding an estimated $275K. The largest seller was Newtyn Management, cutting an estimated $139K.
- 31 institutional investors held Forte Biosciences (FBRX) as of Q1 2023, down from 34 in Q4 2022.
- Funds reported $3.9M of Forte Biosciences stock for Q1 2023, up 2.7% quarter-over-quarter.
- 0 funds opened new Forte Biosciences positions in Q1 2023 and 3 closed out, a net change of -3 holders.
- The largest Forte Biosciences buyer in Q1 2023 was BML Capital Management, an estimated $275K added.
- The largest Forte Biosciences seller in Q1 2023 was Newtyn Management, an estimated $139K sold.
Based on aggregated 13F filings for Q1 2023.